Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2026.07.028 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Dirk J Blom und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Lipidology and Cape Heart Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa (Blom). Electronic address:…. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Benzimidazoles, Homozygote, Hyperlipoproteinemia Type II. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiesi Pharmaceuticals SpA.
Abstract (Originalsprache)
BACKGROUND: Lomitapide is an oral microsomal triglyceride transfer protein inhibitor approved for homozygous familial hypercholesterolemia (HoFH). OBJECTIVE: Evaluate data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER; NCT02135705). METHODS: LOWER is a global, prospective observational registry initiated in March 2014 to evaluate the real-world effectiveness and safety of lomitapide in patients with HoFH. RESULTS: A total of 246 individuals were enrolled (43.5% male; mean age 50.3 years, SD 15.3; range 18-83). Mean lomitapide daily dose was 12.1 mg (SD 8.7; range 1.4-50.0). Patients received lomitapide for an average of 45.6 months (SD 38.4; range 0.3-142.1). Baseline mean low-density lipoprotein cholesterol (LDL-C) was 241.1 mg/dL (SD 109.1; range 71-672). Following treatment initiation, 86.8% of patients on lomitapide achieved ≥50% LDL-C reduction at some time point (72.2% in the full analysis set [FAS]). In the FAS, 74.3% achieved LDL-C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Lipidology and Cape Heart Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa (Blom). Electronic address: dirk.blom@uct.ac.za.
- Department of Hepato-Gastroenterology, University Hospital of Montpellier, Montpellier, France (Larrey).
- Stathmi, Inc, New Hope, PA, United States (Makris).
- Department of Medicine, NYU Grossman School of Medicine, New York, NY, United States (Underberg).
- Chiesi Ltd, Dublin, Ireland (O'Brien).
Förderung
- Chiesi Pharmaceuticals SpA
Zitieren
APA
Blom, D. J., Larrey, D., Makris, L., Underberg, J., & O'Brien, S. (2026). Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.07.028
Vancouver
Blom DJ, Larrey D, Makris L, Underberg J, O'Brien S. Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.07.028
BibTeX
@article{Blom2026,
author = {Blom, Dirk J and Larrey, Dominique and Makris, Lukas and Underberg, James and O'Brien, Sallyann},
title = {Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.07.028}
}
EUVIMED